Evidence map›Paper›PMID 36176410›Full record

ArticleFrontiers in oncology2022

Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade.

Jean-Michel Lavoie, Priya Baichoo, Elizabeth Chavez, Lucia Nappi, Daniel Khalaf, Christian K Kollmannsberger, Kim N Chi, Andrew Weng, Christian Steidl, Bernhard J Eigl and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jean-Michel LavoieDepartment of Medical Oncology, BC Cancer - Surrey Centre, Surrey, BC, Canada.
Priya BaichooTerry Fox Laboratories, Vancouver, BC, Canada.
Elizabeth ChavezCentre for Lymphoid Cancer, BC Cancer Research Centre, Vancouver, BC, Canada.
Lucia NappiDepartment of Medical Oncology, BC Cancer - Vancouver Centre, Vancouver, BC, Canada.
Daniel KhalafDepartment of Medical Oncology, BC Cancer - Vancouver Centre, Vancouver, BC, Canada.
Christian K KollmannsbergerDepartment of Medical Oncology, BC Cancer - Vancouver Centre, Vancouver, BC, Canada.
Kim N ChiDepartment of Medical Oncology, BC Cancer - Vancouver Centre, Vancouver, BC, Canada.
Andrew WengTerry Fox Laboratories, Vancouver, BC, Canada.
Christian SteidlDepartment of Medical Oncology, BC Cancer - Vancouver Centre, Vancouver, BC, Canada.
Bernhard J EiglDepartment of Medical Oncology, BC Cancer - Vancouver Centre, Vancouver, BC, Canada.
Michael NissenTerry Fox Laboratories, Vancouver, BC, Canada.
Terry Fox Research Institute · CASurrey Place Centre · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICI) are used in the treatment of urothelial and renal cell cancers. While some patients may have exceptional responses, better predictive biomarkers are needed. We profiled the circulating immune compartment of patients receiving ICI to identify possible immune markers associated with immunotherapy response or resistance. Peripheral blood samples were collected prior to, and 3 weeks after initiation of ICI. Using mass cytometry, 26 distinct immune populations were identified. Responders to immune checkpoint inhibitors had higher frequencies of naïve CD4+ T-cells, and lower frequencies of CD161+ Th17 cells and CCR4+ Th2 cells. Non-responders had a higher frequency of circulating PD1+ T-cells at baseline; there was a subsequent decrease in frequency with exposure to ICI with a concomitant increase in Ki67 expression. Flow cytometry for cytokines and chemokine receptors showed that CD4+ T cells of non-responder patients expressed less CXCR4 and CCR7. In addition, their PD1- CD4+ T cells had higher TNFα and higher CCR4 expression, while their PD1+ CD4+ T cells had higher interferon γ and lower CCR4 expression. The role of γ/δ T-cells was also explored. In responders, these cells had higher levels of interferon γ, TNFα and CCR5. One patient with a complete response had markedly higher frequency of γ/δ T-cells at baseline, and an expansion of these cells after treatment. This case was analyzed using single-cell gene expression profiling. The bulk of the γ/δ T cells consisted of a single clone of Vγ9/Vδ2 cells both before and after expansion, although the expansion was polyclonal. Gene expression analysis showed that exposure to an ICI led to a more activated phenotype of the γ/δ T cells. In this study, the circulating immune compartment was shown to have potential for biomarker discovery. Its dynamic changes during treatment may be used to assess response before radiographic changes are apparent, and these changes may help us delineate mechanisms that underpin both response and resistance to ICI. It also hypothesizes a potential role for γ/δ T cells as effector cells in some cases.

Indexed as

checkpoint blockadeclinical outcomescytometryimmunotherapyscRNAseq

Identifiers

PMID36176410
PMCPMC9513023
OpenAlexW4295745238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.